Literature DB >> 22288598

Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.

H Karlsson1, T Erkers, S Nava, S Ruhm, M Westgren, O Ringdén.   

Abstract

Bone marrow-derived mesenchymal stromal cells (BM-MSCs) have immunosuppressive properties and have been used to treat steroid-refractory acute graft-versus-host disease (GVHD) in stem cell transplant patients. Cells with similar capacities can also be found in term placental tissue. We have isolated stromal cells from term fetal membrane (FMSCs), umbilical cords (UCSCs) and placental villi (PVSCs) as well as from bone marrow and compared their immunoregulatory capacity in allogeneic settings. We found that FMSCs and UCSCs suppressed proliferation significantly in mixed lymphocyte reactions (MLRs), whereas PVSCs showed inconsistent suppressive effects. When added to MLR cultures, FMSCs suppressed the production of interferon (IFN)-γ and interleukin (IL)-17, whereas UCSCs and PVSCs promoted the production of IL-17 instead. Secretion of IL-10 was increased after addition of FMSCs and UCSCs. In this setting, BM-MSCs had no significant effect on secretion of IFN-γ, IL-17 or IL-10 in MLR cultures. When analysing the expression of adhesion markers, we noted that FMSCs expressed the highest levels of CD29 (β1), CD49d (α4) and CD54 (ICAM-1) compared to the other types of stromal cells. Thus, our data indicate that stromal cells isolated from term fetal membrane have great immunosuppressive capacity in terms of proliferation and production of proinflammatory cytokines from alloreactive T cells, and also promote anti-inflammatory IL-10. They express high levels of integrins that may be of importance in homing to inflamed tissues. Fetal membrane may provide a valuable source of cells with immunosuppressive properties and could possibly be used for treatment of acute GVHD and other inflammatory disorders.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22288598      PMCID: PMC3374287          DOI: 10.1111/j.1365-2249.2011.04540.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  49 in total

1.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

Authors:  Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord.

Authors:  Hwai-Shi Wang; Shih-Chieh Hung; Shu-Tine Peng; Chun-Chieh Huang; Hung-Mu Wei; Yi-Jhih Guo; Yu-Show Fu; Mei-Chun Lai; Chin-Chang Chen
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

3.  Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells.

Authors:  Zhenxing Guo; Cuiling Zheng; Zhenping Chen; Dongsheng Gu; Weiting Du; Jing Ge; Zhongchao Han; Renchi Yang
Journal:  Eur J Immunol       Date:  2009-10       Impact factor: 5.532

Review 4.  The role of allogenic amniotic membrane in burn treatment.

Authors:  Marco Rainer Kesting; Klaus-Dietrich Wolff; Bettina Hohlweg-Majert; Lars Steinstraesser
Journal:  J Burn Care Res       Date:  2008 Nov-Dec       Impact factor: 1.845

5.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

6.  Immunosuppression by placental indoleamine 2,3-dioxygenase: a role for mesenchymal stem cells.

Authors:  B J Jones; G Brooke; K Atkinson; S J McTaggart
Journal:  Placenta       Date:  2007-08-22       Impact factor: 3.481

7.  Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6.

Authors:  B Chen; J Hu; L Liao; Z Sun; Q Han; Z Song; R C Zhao
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

Review 8.  Human fetal membranes: a source of stem cells for tissue regeneration and repair?

Authors:  S Ilancheran; Y Moodley; U Manuelpillai
Journal:  Placenta       Date:  2008-11-07       Impact factor: 3.481

9.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

Authors:  Katarina Le Blanc; Charlotte Tammik; Kerstin Rosendahl; Eva Zetterberg; Olle Ringdén
Journal:  Exp Hematol       Date:  2003-10       Impact factor: 3.084

10.  Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon.

Authors:  O Ringdén; M Uzunel; B Sundberg; L Lönnies; S Nava; J Gustafsson; L Henningsohn; K Le Blanc
Journal:  Leukemia       Date:  2007-07-05       Impact factor: 11.528

View more
  39 in total

1.  In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity.

Authors:  Juan J Montesinos; María de L Mora-García; Héctor Mayani; Eugenia Flores-Figueroa; Rosario García-Rocha; Guadalupe R Fajardo-Orduña; Marta E Castro-Manrreza; Benny Weiss-Steider; Alberto Monroy-García
Journal:  Stem Cells Dev       Date:  2013-06-14       Impact factor: 3.272

Review 2.  Placental-derived stem cells: Culture, differentiation and challenges.

Authors:  Maira S Oliveira; João B Barreto-Filho
Journal:  World J Stem Cells       Date:  2015-05-26       Impact factor: 5.326

Review 3.  Fetal endothelial and mesenchymal progenitors from the human term placenta: potency and clinical potential.

Authors:  Abbas Shafiee; Nicholas M Fisk; Dietmar W Hutmacher; Kiarash Khosrotehrani; Jatin Patel
Journal:  Stem Cells Transl Med       Date:  2015-03-13       Impact factor: 6.940

Review 4.  Stromal cells-are they really useful for GVHD?

Authors:  H Kaipe; T Erkers; B Sadeghi; O Ringdén
Journal:  Bone Marrow Transplant       Date:  2014-01-27       Impact factor: 5.483

Review 5.  Placenta-based therapies for the treatment of epidermolysis bullosa.

Authors:  Christopher Nevala-Plagemann; Catherine Lee; Jakub Tolar
Journal:  Cytotherapy       Date:  2015-03-18       Impact factor: 5.414

6.  Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.

Authors:  Helen Kaipe; Lena-Maria Carlson; Tom Erkers; Silvia Nava; Pia Molldén; Britt Gustafsson; Hua Qian; Xiaoguang Li; Takashi Hashimoto; Behnam Sadeghi; Mats Alheim; Olle Ringdén
Journal:  Stem Cells Dev       Date:  2015-03-13       Impact factor: 3.272

Review 7.  Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Authors:  Allison R Keith; Kirk Twaroski; Christen L Ebens; Jakub Tolar
Journal:  Expert Opin Biol Ther       Date:  2020-03-20       Impact factor: 4.388

Review 8.  Immunological basis for treatment of graft versus host disease after liver transplant.

Authors:  Vikrant Rai; Nicholas Edward Dietz; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-02-24       Impact factor: 4.473

9.  Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling.

Authors:  Tom Erkers; Helen Kaipe; Silvia Nava; Pia Molldén; Britt Gustafsson; Rimma Axelsson; Olle Ringdén
Journal:  Stem Cells Dev       Date:  2015-01-15       Impact factor: 3.272

10.  Treatment of Hemophilia A in Utero and Postnatally using Sheep as a Model for Cell and Gene Delivery.

Authors:  Christopher D Porada; Graça Almeida-Porada
Journal:  J Genet Syndr Gene Ther       Date:  2012-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.